Press release
Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024
* Global Peptide Therapeutics Market Opportunity: More Than US$ 50 Billion
* Cost Analysis & Market Insight into its Application
* Dosage & Sales Analysis of Key Drugs
* Global Peptide Drug Clinical Pipeline: 612 Drugs
* Peptide Drug Application by Indication
* Global Peptide Pipeline by Indication, Company & Phase
* Marketed Peptide Drugs: 101 Drugs
* Clinical Trials Insight by Peptide Classification
Download Report Sample Weblink:
http://www.pnspharma.com/buy-report.php?reporttitle=Global-Peptide-Therapeutics-Market-Dosage-Price-%26-Clinical-Trials-Insight-2024
For Report Sample Contact: rajesh@pnspharma.com
Table of Contents
1. Emergence of Peptide Therapeutics: New Growth Frontier For Pharmaceutical Industry
1.1 Peptides as Drug Candidates
1.2 Why Need for Peptide Therapeutics?
2. Cusp of Small Molecules & Proteins
2.1 Peptides v/s Small Molecules
2.2 Peptides v/s Protein Biologics
3. Fundamentals of Peptide Therapeutics
3.1 Rational Design for Novel Peptides
3.2 Aspects of Regulatory Approvals
4. Peptide Therapeutics – Cost Analysis & Market Insight into its Application
4.1 Application of Peptides in Imaging
4.2 Application of Peptides in Diseases
5. Peptide Therapeutics For Treatment of Metabolic Disorder
5.1 Prologue to Metabolic Disorders
5.2 Approved Peptide Drugs for Metabolic Disorders – Cost & Dosage Analysis
5.3 Market of Metabolic Peptides
6. Peptide Therapeutics in Cancer – Drug Price & Therapy Cost Analysis
6.1 Prologue to Cancer
6.2 Dose & Price Analysis of Peptide Cancer Therapeutics
6.2.1 Abralix
6.2.2 Degarelix
6.2.3 Octreotide
6.2.4 Leuprolide
6.2.5 Sipuleucel-T ( Provenge)
6.2.6 Goserelin (Zoladex)
6.3 Cancer Peptide Therapeutics – Sales Analysis
7. Peptide Therapeutics For Treatment of Cardiovascular Disease
7.1 Prologue to Cardiovascular Diseases
7.2 Approved Peptide Drugs in Cardiovascular Diseases
7.3 Cardiac Peptide Therapeutics – Sales Analysis
8. Peptide Therapeutics For Treatment of HIV Infections
8.1 Prologue to Infections
8.2 Approved Peptide Therapeutics in Infections
8.3 Anti-Infectious Peptides – Sales Analysis
9. Peptide Therapeutics For Treatment of CNS Disorders
9.1 Prologue to CNS Disorders
9.2 Neuropeptides Drug Delivery to CNS
9.3 Future Market Potential
10. Global Peptide Therapeutics Market Current Scenario
10.1 Overview
10.2 Peptide Market by Application
11. Global Peptides Drug Clinical Pipeline Overview
11.1 Cyclic Peptides
11.2 Depsipeptides
11.3 Dipeptides
11.4 Glycopeptides
11.5 Lipopeptides
11.6 Natriuretic Peptides
11.7 Neuropeptides
11.8 Oligopeptides
11.9 Opioid Peptides
11.10 Peptides
11.11 Multiple Peptides
12. Global Peptide Market by Route of Administration
12.1 Current Trends in Route of Administration
12.2 Current Trends over the Peptide Products
13. Global Peptide Market by Region
13.1 North America
13.2 Europe
13.3 Asia
14. Global Peptide Drug Market Dynamics
14.1 Favorable Parameters
14.2 Challenges
15. Global Peptide Therapeutics Market Future Outlook
15.1 Future Trends in Peptide Therapeutics
15.2 Future Opportunities of Peptides Therapeutics
16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company
16.1 Preclinical till Preregistration
16.2 Marketed
17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company
17.1 Preclinical till Preregistration
17.2 Marketed
18. Dipeptides Clinical Trials Insight by Phase, Indication & Company
18.1 Preclinical till Preregistration
18.2 Marketed
19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company
19.1 Preclinical till Preregistration
19.2 Marketed
20. Lipopeptides Clinical Trials Insight by Phase, Indication & Company
20.1 Preclinical till Preregistration
21. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company
21.1 Preclinical till Preregistration
21.2 Marketed
22. Neuropeptides Clinical Trials Insight by Phase, Indication & Company
22.1 Preclinical till Preregistration
22.2 Marketed
23. Oligopeptides Clinical Trials Insight by Phase, Indication & Company
23.1 Preclinical till Preregistration
23.2 Marketed
24. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company
24.1 Preclinical till Preregistration
24.2 Marketed
25. Peptides Clinical Trials Insight by Phase, Indication & Company
25.1 Preclinical till Preregistration
25.2 Marketed
26. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company
26.1 Preclinical till Preregistration
26.2 Marketed
27. Competitive Landscape
27.1 Amgen
27.2 Amylin Pharmaceuticals
27.3 Apitope Technology
27.4 BioPartners
27.5 BiondVax Pharmaceuticals Ltd
27.6 Boehringer Ingelheim
27.7 Circassia
27.8 Corden Pharma (Peptisyntha)
27.9 Eli Lily
27.10 Galena Biopharmaceuticals
27.11 GlaxoSmithKline
27.12 Hyperion Therapeutics
27.13 ImmunoCellular Therapeutics
27.14 Ipsen
27.15 Lonza
27.16 Merck
27.17 NovoNordisk
27.18 Par Pharmaceuticals
27.19 PeptiDream
27.20 Roche
27.21 Sanofi
27.22 Tarix Pharmaceuticals
Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
Figure 2-2: Layout of Advantages of Peptide Drugs
Figure 3-1: Classification Based over the Sources of Peptide
Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
Figure 4-1: Global- Imaging Technology Market by Usage (%), 2018
Figure 4-2: Healthcare Imaging Market Share by Company (%), 2018
Figure 4-3: Diagrammatic Representation of the Peptidic Probe
Figure 4-4: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
Figure 4-5: Global - Peptide Therapeutics Market Size by Clinical Indications, 2018
Figure 5-1: Global - Prevalence of Metabolic Disorders by Region (%), 2018
Figure 5-2: Layout of Metabolic Syndrome Leading to Several Diseases
Figure 5-3: Global - Top 10 Countries with Diabetes Burden (Million), 2030
Figure 5-4: Global – Obesity in Women & Men by Region (Million), 2018
Figure 5-5: US– GLP-1 Agonist Drugs Comparative Cost Analysis (US$), 2018
Figure 5-6: Lantus – Monthly Cost Comparison by Country (US$), 2018
Figure 5-7: Global – Metabolic Peptide Market Size (%), 2018
Figure 6-1: Global - Cancer Cases per 100,000 People (Top 10), 2018
Figure 6-2: Abraxis - Dosage Analysis (Mg/Day)
Figure 6-3: Degarelix - Dose Analysis (Mg/Patient)
Figure 6-4: Degarelix - Price Analysis (US$/Injection Vial), 2018
Figure 6-5: Degarelix-Monthly & Annual Treatment Cost Analysis (US$/Patient), 2018
Figure 6-6: Octerotide - Recommended Dosage for Carcinoid Tumor (Mcg/Patient)
Figure 6-7: Octreotide - Recommended Dosage for VIPOmas (Mcg/Patient)
Figure 6-8: Octreotide - Injectable Solution Price Analysis (US$/Mcg Vial), 2018
Figure 6-9: Leuprolide -Adult Dosage Analysis for Prostate Cancer by Month (Mg)
Figure 6-10: Leuprolide -Adult Dosage Analysis for Endometriosis in Women (Mg)
Figure 6-11: Provenge - Price Analysis (US$), 2018
Figure 6-12: Global - Cancer Peptide Therapeutics Market Size (%), 2018
Figure 6-13: US - Velcade Market Sales (US$ Million), 2018
Figure 6-14: Global – Estimated Velcade Sales (US$ Billion), 2018 - 2024
Figure 6-15: Global - Kyprolis Saless (US$ Billion), 2013 - 2017
Figure 6-16: Global & US - Zoladex Sales (US$ Million), 2017
Figure 7-1: Global - Cardiovascular Mortality (%), 2018
Figure 7-2: Cardiovascular Peptide Therapeutics - Cost Analysis (US$//Patient), 2018
Figure 7-3: Global - Angiomax Sales (US$ Million), 2018
Figure 7-4: Global - Integrilin Sales (US$ Million), 2016 & 2017
Figure 8-1: Global - Top 10 Leading Causes of Death
Figure 8-2: Global – Distribution of AIDS Affected Patients by Region (%), 2018
Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2015 - 2017
Figure 9-1: US - Prevalence of Alzheimer’s disease (Million)
Figure 9-2: Alzheimer Disease Market Size (%), 2018
Figure 10-1: Global - Insulin Market Forecast (US$ Billion) 2018 - 2024
Figure 11-1: Global - Total Peptides Clinical Pipeline by Phase (%), 2018 till 2024
Figure 11-2: Global Total Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-3: Global Cyclic Peptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-4: Global Cyclic Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-5: Global Depsipeptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-6: Global Depsipeptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-7: Global Dipeptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-8: Global Dipeptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-9: Global Glycopeptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-10: Global Glycopeptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-11: Global Lipopeptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-12: Global Lipopeptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-13: Global Natriuretic Peptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-14: Global Natriuretic Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-15: Global Neuropeptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-16: Global Neuropeptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-17: Global Oligopeptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-18: Global Oligopeptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-19: Global Opioid Peptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-20: Global Opioid Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-21: Global Peptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-22: Global Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 11-23: Global Multiple Peptides Clinical Pipeline by Phase (%),2018 till 2024
Figure 11-24: Global Multiple Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 12-1: Therapeutic Peptide Based Drugs over Route of Administration
Figure 14-1: Illustration of Peptide Therapeutics Market Drivers
Figure 14-2: Major Challenges Faced by the Peptide Therapeutics
Figure 15-1: Global – Estimated Future Peptide Therapeutics Market Size by Clinical Indication (%), 2024
Figure 15-2: Global - Cancer Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024
Figure 15-3: Global - Metabolic Disorders Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024
Figure 15-4: Global - Cardiovascular Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024
Figure 15-5: Global - CNS, HIV & Infection Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024
Figure 15-6: Future Trends of Peptide Therapeutics
Figure 15-7: Global - Peptide Therapeutics Market Forecast (US$ Billion), 2018 - 2024
List of Tables
Table 2-1: Comparative Analysis of Small Molecules & Peptide Drugs
Table 2-2: Comparative Differentiation between Peptide & Protein Drugs
Table 5-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
Table 5-2: Layout of Insulin & its Analogs Cost in US
Table 6-1: Approved Commercialized Peptide Cancer Drugs
Table 7-1: Approved Peptide Drugs for Cardiovascular Diseases
Table 8-1: Approved Drugs for Infections
Table 9-1: Brief Characterization of Some Neuroprotective Peptides
Table 9-2: Potential Targets for Peptide Based Therapies in CNS Disorders
Table 12-1: List of Approved Peptide Drugs Since 2000
PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.
Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024 here
News-ID: 1059094 • Views: …
More Releases from PNS Pharma
Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight:
o Global Gene Therapy Market Opportunity: > US$ 8 Billion
o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials
o Commercially Available Gene Therapies: 11
o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials
o Cancer Accounts For 50% of Global Gene Therapy Trials
Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026
Over the years, gene therapy has been highly responsible for decreasing the mortality rate…
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
o Global Orphan Drug Market Opportunity: US$ 300 Billion
o US Dominates Global Orphan Drug Market: 50% Market Share
o US Orphan Drug Opportunity To Surpass: US$ 150 Billion
o Global Orphan Drug Clinical Insight: More Than 900 Drugs
o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
o Oncology To Dominate Orphan Drug Development: 35% Share
o FDA & EMA Regulations For Orphan Drugs
o Orphan Drug Designation Criteria…
More Releases for Peptide
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
What's driving the Customized Peptide Synthesis Market Growth? | Key Players are …
The customized peptide synthesis market is projected to generate a revenue of $390.0 million by 2024 as per a recent P&S Intelligence study. The market is being progressively driven by technological innovations, growing burden of cancer and infectious diseases, increasing investments and funding for protein-based research, and rising research activities in synthetic biology.
Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample
There are two main types of products available in the customized peptide synthesis…
Customized Peptide Synthesis Market 2019-2024 by Top Key Players are GenScript, …
Customized peptide synthesis market is forecasted to generate revenue of $390.0 million by 2024. The market is mainly driven by increasing investments and funding for protein-based research, technological innovations, growing burden of cancer and infectious diseases, and increasing research activities in the field of synthetic biology.
Download free report sample at: https://www.psmarketresearch.com/market-analysis/customized-peptide-synthesis-market/report-sample
The different types of products available in the customized peptide synthesis market are reagents and equipment. Reagents category is expected…
Peptide Synthesis Market Increasing Demand & Latest Trend with Genscript, AnaSpe …
HTF MI recently introduced United States Peptide Synthesis Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Bachem, PolyPeptide, GL Biochem, Xinbang, Hybio, USVPeptides, Thermofischer, ScinoPharm, Genscript,…
Global Peptide Therapeutics Market: Cancer Treatment to Surface as Key Applicati …
Market Research Reports Search Engine (MRRSE) has been acting as an impressive data source when it comes to evaluating various industrial verticals. The research report titled “Global Peptide Therapeutics Market” offers a clear insight about the Peptide Therapeutics assessed over the global platform. This analysis proves beneficial for readers & new investors who are aiming to enter the market for Peptide Therapeutics in the near future.
Click to Request a Sample:…
Peptide Based Cancer Therapeutics Marke For peptide based cancer therapeutics ov …
About Peptide Based Cancer Therapeutics Market
Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug…
